171 related articles for article (PubMed ID: 38182630)
1. Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
González-Moreno J; Gragera-Martínez Á; Rodríguez A; Borrachero-Garro C; García-Garrido S; Barceló C; Manovel-Sánchez A; Ribot-Sansó MA; Ibargüen-González L; Gomila R; Muñoz-Beamud F; Losada-López I; Cisneros-Barroso E
Sci Rep; 2024 Jan; 14(1):581. PubMed ID: 38182630
[TBL] [Abstract][Full Text] [Related]
2. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
3. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
[TBL] [Abstract][Full Text] [Related]
5. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
Amyloid; 2024 Feb; ():1-10. PubMed ID: 38348665
[TBL] [Abstract][Full Text] [Related]
6. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.
Maia LF; Maceski A; Conceição I; Obici L; Magalhães R; Cortese A; Leppert D; Merlini G; Kuhle J; Saraiva MJ
Amyloid; 2020 Jun; 27(2):97-102. PubMed ID: 31906707
[No Abstract] [Full Text] [Related]
7. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
[TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
10. Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.
Hood CJ; Hendren NS; Pedretti R; Roth LR; Saelices L; Grodin JL
Curr Heart Fail Rep; 2022 Oct; 19(5):356-363. PubMed ID: 35930129
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Mar; ():1-10. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
12. Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.
Leonardi L; Adam C; Beaudonnet G; Beauvais D; Cauquil C; Not A; Morassi O; Benmalek A; Trassard O; Echaniz-Laguna A; Adams D; Labeyrie C
Eur J Neurol; 2022 May; 29(5):1477-1487. PubMed ID: 35100482
[TBL] [Abstract][Full Text] [Related]
13. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
[TBL] [Abstract][Full Text] [Related]
14. Validating the usefulness of Sudoscan in ATTRv: a single centre experience.
Moreno-Moraleda E; González-Moreno J; Cisneros-Barroso E; Ribot-Sansó MA; Ripoll-Vera T; Descals C; Uson M; Montalà JC; Figuerola A; Rodríguez A; Losada I
Neurol Sci; 2024 Jun; 45(6):2859-2867. PubMed ID: 38261153
[TBL] [Abstract][Full Text] [Related]
15. Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.
Matsushita H; Misumi Y; Masuda T; Okada M; Inoue F; Ueda M; Ando Y
Pathophysiology; 2022 Jun; 29(3):333-343. PubMed ID: 35893595
[TBL] [Abstract][Full Text] [Related]
16. Axonal excitability as an early biomarker of nerve involvement in hereditary transthyretin amyloidosis.
Carroll AS; Park SB; Lin CSY; Taylor MS; Kwok F; Simon NG; Reilly MM; Kiernan MC; Vucic S
Clin Neurophysiol; 2024 Mar; 159():81-95. PubMed ID: 38377648
[TBL] [Abstract][Full Text] [Related]
17. Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study.
Vegezzi E; Cortese A; Bergsland N; Mussinelli R; Paoletti M; Solazzo F; Currò R; Ascagni L; Callegari I; Quartesan I; Lozza A; Deligianni X; Santini F; Marchioni E; Cosentino G; Alfonsi E; Tassorelli C; Bastianello S; Merlini G; Palladini G; Obici L; Pichiecchio A
J Neurol; 2023 Jan; 270(1):328-339. PubMed ID: 36064814
[TBL] [Abstract][Full Text] [Related]
18. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis.
Zampino S; Sheikh FH; Vaishnav J; Judge D; Pan B; Daniel A; Brown E; Ebenezer G; Polydefkis M
Neurology; 2023 May; 100(19):e2036-e2044. PubMed ID: 36941075
[TBL] [Abstract][Full Text] [Related]
19. Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country.
Koutsis G; Kastritis E; Kontogeorgiou Z; Kartanou C; Kokotis P; Rentzos M; Breza M; Kleopa KA; Christodoulou K; Oikonomou E; Anastasakis A; Angelidakis P; Sarmas I; Kargiotis O; Tzagournissakis M; Zaganas I; Foukarakis E; Sachpekidis V; Papathoma A; Panas M; Stefanis L; Dimopoulos MA; Karadima G
Neuromuscul Disord; 2021 Dec; 31(12):1251-1258. PubMed ID: 34740514
[TBL] [Abstract][Full Text] [Related]
20. Hereditary Transthyretin Amyloidosis- Clinical and Genetic Characteristics of a Multiracial South-East Asian Cohort in Singapore.
Chen Z; Koh JS; Saini M; Tay KSS; Jayne Tan Y; Chai JYH; Fam SR; Juraidah AR; Lim PK; Ng ASL; Prasad K; Tan CB; Umapathi T; Verma KK; Yong MH; Yu C; Ng PS
J Neuromuscul Dis; 2021; 8(4):723-733. PubMed ID: 34024775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
